Search results
Showing 901 to 915 of 1214 results for pain
NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .
Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.
Bortezomib for previously untreated mantle cell lymphoma (TA370)
Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.
Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.
Transperineal biopsy for diagnosing prostate cancer (HTG680)
Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer.
Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal.
Read the biographies of our medical technologies advisory committee members.
Read the biographies of our medical technologies advisory committee members.
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
monitoring of temperature and level of consciousness (AVPU [alert, voice, pain, unresponsive]), and 4‑hourly monitoring of respiratory...
NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.